Menu
Search Close

News

Helium Special Situations increases interest in Scancell

17th November 2011

Holdings in Company

 The Company announces that it has received notification that Helium Special Situations Fund Limited has increased its beneficial interest in Scancell Holdings to 17,586,940 ordinary shares of 0.1 pence each which represents approximately 9.06 per cent of the issued capital of the Company.

 For further information contact:

 Scancell Holdings Plc 

Professor Lindy Durrant/Dr Richard Goodfellow

+ 44 (0)207 245 1100

 

Hansard Communications- Financial PR 

Adam Reynolds/Guy McDougall

+ 44 (0)207 245 1100

 

Zeus Capital - Nominated Adviser

Ross Andrews/Tom Rowley

+ 44 (0)161 831 1512

 

XCAP Securities Plc - Broker

Jon Belliss/ Adrian Kirk

+44 (0) 207 101 7070

Webcasts, Interviews and Media Coverage

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Thu, 09 Aug 2018 10:48:00

Scancell Holdings extends collaboration with Sweden's Karolinska Institute

The company first teamed up with Sweden's world-leading medical research university two years ago

Thu, 09 Aug 2018 08:15:00

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems

Wed, 18 Jul 2018 06:09:00